Nov-2017

28 29 XYMOGEN “Prior to the internet,maintaining this exclusivity was not very difficult to do,”Blackburn recounts.“But around 1999, it started becoming a major challenge.” When he pointed out to company heads that con- sumers were,more and more frequently, buying sup- plements direct from distributors, online, he expected that they would look for ways to protect practitioner exclusivity. Instead,“they went and set up a website to actually promote the formulas direct to the con- sumer, thereby bypassing the very practitioners that contributed most to the success of the company. So, in light of that,we decided that there’s a better way to do this; that it is possible to build a truly exclusive formula and company. So,we launched Xymogen with that premise.” Blackburn also made some other improvements to existing business models.“Our former company never had anymedical board advisors,”he relates.“They really didn’t listen to the distributors–I was one of twelve–nor to our customers, and without medi- cal advice,without listening,many of the formulas became out of date. So, our goal was to create a truly exclusive line of formulas, create a medical board of advisors as a sounding board for our customers, and then the third most important component was inno- vation.”Xymogen’s 40-member medical board does meet in person, twice a year, and spends two days reviewing formulas to ascertain that they are based on the latest science.“Those are the three reasons– exclusivity,medical board advisors, and innovation– that we thought there was a void in the marketplace, and we wanted to fill that void.And I think we’ve done so, pretty well.” Today,Xymogen supplies approximately 12,000 practitioners, offering over 400 products made from 1,200 different ingredients. Its biggest mar- kets are the United States and Canada, but it also has clients in South Korea, South Africa, Indonesia, B CM-95® is one of the most widely sold curcumin products on the market. It is the feature ingre- dient in Xymogen’s top-selling curcumin standalone product, Curcuplex-95™ and plays a supportive role in many of their other exclusive formulations. The pop- ularity of the brand is owed to its patented composi- tion of high-potency curcuminoids and complementary essential oils sourced from the same turmeric material. This unique composition affords the enhanced bioavail- ability and efficacy associated with the trademark. In fact, BCM-95® has been the subject of over 30 peer-re- viewed publications establishing its health promoting role in more than 15 different conditions. I nflammation has become the nefarious target of the chronic disease process and curcumin has been proven to regulate the many cell signaling molecules, receptors and transcription factors involved in this response. However, actualizing these results in the clinical setting has been the bane of this molecule’s existence. The low bioavailability of curcumin has been known for more than 15 years. Combining the extract with novel blends of solubilizers, bio-enhancers, or other adjuvants has allowed many companies to enter the curcumin market and claim for the enhancement of bioavailability, but very few have gained stake as clini- cally-vetted solutions to the problem. BCM-95®, with its 14-year track record for safety and efficacy with- out the use of non-turmeric derived excipients has not only survived among its competitors, but thrives with an Indian export ranking among the top 3 for turmeric products for dietary supplement use. E xtensive inquiry from the scientific community has prompted the majority of consumer aware- ness about curcumin. A 2017 SPINS market research report ranked turmeric as the top-selling herbal sup- plement in 2016, with total sales in the US channels of $47.6 million and a percent change from 2015 of 32%. This trend does not seem to be on the decline, as forecasts from a 2016 Global Market Insights re- port suggests a market size of 99.3 million dollars in 2024. With the exclusive North American distribution rights to BCM-95 owned and operated by trademark holder, DolCas Biotech, LLC - BCM-95® continues to position itself for an upward trajectory. DolCas’ verti- cally-integrated relationship with the product’s Indi- an-based manufacturer, Arjuna Naturals has stream- lined appraisal efforts for safe use while continuing to evolve its proof of efficacy through scientific rigor. D olCas Biotech will close out the year with major milestones including a FDA notification conclud- ing no further inquiry into BCM-95’s self-affirmed Generally Recognized as Safe (GRAS) distinction, as well as two published studies. Three additional studies are slated for publication in 2018. The brand’s strong staying power is demonstrated by its bench- mark status in leading nutraceutical lines as the ONLY 100% turmeric-derived, essential oil enhanced, patented curcumin product for bioavailability and bio-efficacy. Curcumin in today’s market remedy clinically proven with essential oils from turmeric. www.Dolcas-Biotech.com info@dolcas-biotech.com Also ask about: Amlamax ® , Biolane ® , BosPure ® 4 www.dolcas-biotech.com